^
    CANCER:

    Lymphoma

    Contact us to learn more about our Premium Content:
    News alerts, weekly reports and conference planners
    Related cancers:
    No biomarker
    Non-Hodgkin’s Lymphoma
    valemetostat
    Sensitive
    :
    A1
    Daiichi Sankyo Press Release - 1 day - (New A1)
    Chr del(11q)
    Small Lymphocytic Lymphoma
    zanubrutinib
    Sensitive
    :
    B
    SOHO 2022 - 6 days - (New B)
    MYD88 mutation
    Waldenstrom Macroglobulinemia
    zanubrutinib
    Sensitive
    :
    B
    SOHO 2022 - 6 days - (New B)
    TNFRSF8 positive
    Hodgkin Lymphoma
    CD30-targeted CAR-T immunotherapy
    Sensitive
    :
    C3
    SOHO 2022 - 6 days - (New C3)
    No biomarker
    Hodgkin Lymphoma
    rituximab / hyaluronidase
    Sensitive
    :
    A2
    NCCN - 1 week - (New A2)
    No biomarker
    T Cell Non-Hodgkin Lymphoma
    sugemalimab
    Sensitive
    :
    B
    CStone Pharma Press Release - 2 weeks - (New B)
    No biomarker
    Marginal Zone Lymphoma
    zanubrutinib
    Sensitive
    :
    A1
    No biomarker
    Diffuse Large B Cell Lymphoma
    lisocabtagene maraleucel
    Sensitive
    :
    A1
    No biomarker
    Follicular Lymphoma
    axicabtagene ciloleucel
    Sensitive
    :
    A1
    No biomarker
    Diffuse Large B Cell Lymphoma
    axicabtagene ciloleucel
    Sensitive
    :
    A1
    No biomarker
    Mediastinal B Cell Lymphoma
    axicabtagene ciloleucel
    Sensitive
    :
    A1
    No biomarker
    Mantle Cell Lymphoma
    brexucabtagene autoleucel
    Sensitive
    :
    A1
    No biomarker
    Marginal Zone Lymphoma
    rituximab + lenalidomide
    Sensitive
    :
    A1
    No biomarker
    Non-Hodgkin’s Lymphoma
    brentuximab vedotin
    Sensitive
    :
    A1
    ALK positive
    Non-Hodgkin’s Lymphoma
    crizotinib
    Sensitive
    :
    A1
    No biomarker
    Diffuse Large B Cell Lymphoma
    rituximab
    Sensitive
    :
    A1
    No biomarker
    Lymphoma
    axicabtagene ciloleucel
    Resistant
    :
    A1
    No biomarker
    Diffuse Large B Cell Lymphoma
    tisagenlecleucel-T
    Sensitive
    :
    A1
    CD20 positive
    Diffuse Large B Cell Lymphoma
    Rixathon (rituximab biosimilar)
    Sensitive
    :
    A1
    No biomarker
    Burkitt Lymphoma
    cyclophosphamide
    Sensitive
    :
    A1
    No biomarker
    Burkitt Lymphoma
    rituximab
    Sensitive
    :
    A1
    No biomarker
    Mantle Cell Lymphoma
    orelabrutinib
    Sensitive
    :
    A1
    No biomarker
    Small Lymphocytic Lymphoma
    orelabrutinib
    Sensitive
    :
    A1
    TNFRSF8 positive
    Hodgkin Lymphoma
    brentuximab vedotin
    Sensitive
    :
    A1
    No biomarker
    Mantle Cell Lymphoma
    lenalidomide
    Sensitive
    :
    A1
    CD20 expression
    Non-Hodgkin’s Lymphoma
    rituximab-arrx
    Sensitive
    :
    A1
    No biomarker
    Follicular Lymphoma
    rituximab + lenalidomide
    Sensitive
    :
    A1
    No biomarker
    Hodgkin Lymphoma
    pembrolizumab
    Sensitive
    :
    A1
    No biomarker
    Hodgkin Lymphoma
    carmustine
    Sensitive
    :
    A1
    No biomarker
    Non-Hodgkin’s Lymphoma
    carmustine
    Sensitive
    :
    A1
    CD20 positive
    Diffuse Large B Cell Lymphoma
    rituximab-abbs
    Sensitive
    :
    A1
    No biomarker
    Follicular Lymphoma
    rituximab-abbs
    Sensitive
    :
    A1
    No biomarker
    Follicular Lymphoma
    Rixathon (rituximab biosimilar)
    Sensitive
    :
    A1
    CD20 positive
    Diffuse Large B Cell Lymphoma
    rituximab-pvvr
    Sensitive
    :
    A1
    No biomarker
    Follicular Lymphoma
    rituximab-pvvr
    Sensitive
    :
    A1
    No biomarker
    Hodgkin Lymphoma
    brentuximab vedotin
    Sensitive
    :
    A1
    No biomarker
    Follicular Lymphoma
    obinutuzumab
    Sensitive
    :
    A1
    No biomarker
    Waldenstrom Macroglobulinemia
    zanubrutinib
    Sensitive
    :
    A1
    BeiGene Press Release - 1 week - (New A2)